ATRA · Atara Biotherapeutics, Inc. · Fails to Deliver
$9.38
-0.51 (-5.16%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$94.15M
Shares
10.04M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-08-13 | 1,050 | $9.23 | $9,692 |
| 2026-08-12 | 1,017 | $8.94 | $9,092 |
| 2026-08-11 | 358 | $8.61 | $3,082 |
| 2026-08-06 | 1,748 | $8.54 | $14,928 |
| 2026-08-03 | 164 | $8.38 | $1,374 |
| 2026-07-29 | 2,312 | $7.81 | $18,057 |
| 2026-07-27 | 1,400 | $7.90 | $11,060 |
| 2026-07-24 | 1,731 | $8.17 | $14,142 |
| 2026-07-21 | 1,823 | $8.29 | $15,113 |
| 2026-07-15 | 4,081 | $8.04 | $32,811 |
| 2026-07-13 | 974 | $9.76 | $9,506 |
| 2026-07-08 | 5,649 | $10.26 | $57,959 |
| 2026-07-07 | 12,537 | $10.88 | $136,403 |
| 2026-07-02 | 11,929 | $11.37 | $135,633 |
| 2026-07-01 | 1,400 | $11.48 | $16,072 |
| 2026-06-30 | 1,000 | $11.17 | $11,170 |
| 2026-06-29 | 1,826 | $10.51 | $19,191 |
| 2026-06-26 | 7,404 | $10.22 | $75,669 |
| 2026-06-25 | 505 | $10.55 | $5,328 |
| 2026-06-23 | 1,147 | $10.61 | $12,170 |
| 2026-06-22 | 5,339 | $10.07 | $53,764 |
| 2026-06-18 | 6,788 | $9.67 | $65,640 |
| 2026-06-17 | 236 | $9.62 | $2,270 |
| 2026-06-16 | 1,142 | $9.96 | $11,374 |
Showing 1–24 of 24 settlements
Key facts
CIK
1604464
CUSIP
046513206
13F (30d)
14 filings
14 filers
Visit website
Investor relations